Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference

Reuters

11小时前

Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference

Adlai Nortye Ltd. has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled "Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate $(ADC)$ armed with a proprietary pan-RAS$(ON)$ inhibitor payload, designed to broaden the therapeutic window," is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2575099283"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2575099283\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2575099283?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-14 00:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2575099283","market":"us","top_or_hot":-1,"title":"Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALN\">Adlai Nortye Ltd.</a> has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled \"Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> armed with a proprietary pan-RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitor payload, designed to broaden the therapeutic window,\" is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-14 00:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/ALN\">Adlai Nortye Ltd.</a> has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled \"Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate <a href=\"https://laohu8.com/S/ADC\">$(ADC)$</a> armed with a proprietary pan-RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> inhibitor payload, designed to broaden the therapeutic window,\" is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANL","symbol_name":"阿诺医药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251013:nNDL6vCB78:1","article_id":"2575099283","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2575099283","pubTimestamp":1760371369,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Adlai Nortye Ltd. has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled \"Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate  armed with a proprietary pan-RAS inhibitor payload, designed to broaden the therapeutic window,\" is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nort","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANL":"阿诺医药","IE00BZ199S13.USD":"BNY MELLON MOBILITY INNOVATION \"B\" (USD) ACC","LU2133065610.SGD":"JPMorgan Investment Funds - Global Dividend A (mth) SGD","BK4139":"生物科技"},"translate_title":"Adlai Nortye将在大型癌症会议上展示新型CEACAM5靶向ADC AN4035的有希望的数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANL":0.9},"content_text":"Adlai Nortye to Present Promising Data on Novel CEACAM5-Targeting ADC AN4035 at Major Cancer Conference\n    \n\nAdlai Nortye Ltd. has announced that it will deliver an oral presentation on its novel drug candidate AN4035 at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, scheduled for October 22-26, 2025, in Boston, MA. The presentation, titled \"Discovery of AN4035: A novel CEACAM5-targeting antibody drug conjugate $(ADC)$ armed with a proprietary pan-RAS$(ON)$ inhibitor payload, designed to broaden the therapeutic window,\" is set for October 25, 2025. Further scientific details and data highlights will be released following the public posting of the abstract on the AACR portal on October 22, 2025. The results of the study have not yet been presented.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adlai Nortye Ltd. published the original content used to generate this news brief on October 13, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}